The treatment leverages K-Beauty innovation by delivering nucleotides directly to the skin, which assists in natural repair processes and barrier fortification. By pairing this serum with clinical microneedling, the company aims to move beyond surface-level aesthetics, targeting cellular-level health. Dr. Dean Vistnes, co-founder and medical director, noted that patients are increasingly prioritizing biological skin health over temporary cosmetic fixes.

This launch expands the company's existing Catalyst Serum range, which already features exosome-based solutions and targeted acne treatments. With over 60 locations across the United States, SkinSpirit intends to standardize this advanced regenerative offering nationwide, reinforcing its market position as a high-volume provider of medical-grade facial and body rejuvenation.